Emily Menendez

GU Oncology Now

The American Urological Association (AUA) and the Society of Urologic Oncology (SUO) have updated their <a href="https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer" target="_blank" rel="noopener">clinical practice guideline</a> for the treatment of advanced prostate cancer.The guideline was first published in 2020 and includes recommendations for the treatment and management of biochemical recurrence, metastatic hormone-sensitive prostate cancer (mHSPC), nonmetastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-resistant prostate cancer (mCRPC).The updated guideline emphasizes the use of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging for periodic staging, as well as the inclusion of androgen deprivation therapy (ADT) as a monotherapy or in combination with other treatments.Recommendations found in the updated guideline include:&bull;&nbsp; Clinicians should obtain tissue diagnosis of the primary tumor or metastasis site when feasible for&nbsp; &nbsp;the early evaluation and counseling of patients with suspected advanced prostate cancer.&bull;&nbsp; Clinicians should encourage patient engagement with resources such as patient advocacy groups.&bull;&nbsp; ADT is strongly recommended as a treatment for patients with mHSPC in combination with androgen pathway-directed therapy (abiraterone acetate plus prednisone, apalutamide, enzalutamide) or chemotherapy (docetaxel).&bull;&nbsp; For patients with nmCRPC, serial prostate-specific antigen (PSA) levels should be measured at 3- to 6-month intervals, and PSA doubling time should be calculated at the start of development of castration resistance.&bull;&nbsp; Patients with nmCRPC who are at high risk for developing metastatic disease should be offered apalutamide, darolutamide, or enzalutamide with continued ADT.&bull;&nbsp; Annual imaging is recommended for patients with mCRPC without PSA progression or new symptoms.&bull;&nbsp; In patients who may undergo ADT, clinicians should discuss bone health, including the risk of osteoporosis associated with ADT. The risk of fragility fracture in patients with advanced prostate cancer should be assessed.&bull;&nbsp; After the exhaustion of local treatment options, patients with PSA recurrence should be given periodic staging evaluations consisting of cross-sectional imaging and bone scans or PSMA PET imaging.To view the full list of updated guideline statements, visit <a href="https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer" target="_blank" rel="noopener">auanet.org.</a>

Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing

Prostate Cancer

The updated AUA/SUO guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT alone or in combination with other treatments.

Updated AUA/SUO Guideline on Advanced Prostate Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe